Anbeisi (bevacizumab biosimilar) / Sino Biopharm - LARVOL DELTA

Chinese Regulator Grants Drug Registration Certificate for Sino Biopharmaceutical’s Cancer Treatment (Market Screener) - "China's National Medical Products Administration granted drug registration certificate to Sino Biopharmaceutical's (HKG:1177) Bevacizumab injection, a treatment for cancer, according to a Friday filing. The drug has indications for metastatic colorectal cancer, recurrent glioblastoma, and advanced, metastatic or recurrent nonsmall cell lung cancer."

Non-US regulatory • Brain Cancer • CNS Tumor • Colorectal Cancer • Gastrointestinal Cancer • Glioblastoma • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects. (PubMed, Expert Opin Drug Metab Toxicol) - P1 | "This study showed that bevacizumab biosimilar and Bevacizumab had similar pharmacokinetics (PK) parameters and safety in healthy Chinese subjects. This trial was registered in ClinicalTrials.gov (Number: NCT05476341, date registered: 25, Jul 2022) and Drug Clinical Trial Registration and Information Disclosure Platform (Number: CTR20171308, date registered: 16, Nov 2017)."

Clinical • Journal • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor